Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers, Combined with Dapagliflozin as Type 2 Diabetes Mellitus Routine Treatment: A Controlled Randomized, Double-blind Trial

What Was Tested

This randomized controlled trial paper looks at Cyanocobalamin (Vitamin B12).

Diabetes mellitus is predominantly a growing global problem interconnected proportionally with obesity escalation.

The current study evaluated the prognostic implications of vitamin B12 administration on Body Mass Index (BMI) and glycosylated hemoglobin (HbA1c) levels in type 2 diabetic patients treated with dapagliflozin.

Who Took Part

The abstract describes 2 patients taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The patients were allocated by chance, so the Cyanocobalamin (Vitamin B12) group and the comparison group should start out alike.

As a double-blind Cyanocobalamin (Vitamin B12) study, the assignments were hidden from both participants and investigators until the end.

HbA1c, Vitamin B12, and BMI were measured at time intervals of 0, 6, and 12 months.

The continuous variables were reported as median and IQR.

Mann-Whitney-u test and Correlations Spearman's rho were used for continuous variables.

What Was Measured

The current study evaluated the prognostic implications of vitamin B12 administration on Body Mass Index (BMI) and glycosylated hemoglobin (HbA1c) levels in type 2 diabetic patients treated with dapagliflozin.

The subject headings attached to it are Vitamin B 12, Glucosides, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Benzhydryl Compounds and Body Mass Index.

The authors tagged it with the keywords Dapagliflozin and Vitamin B12.

What This Means in Plain Language

The paper is a randomized and double-blind study of Cyanocobalamin (Vitamin B12) in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Iranian journal of medical sciences), a journal based in Iran.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.